PainChek Secures $1.123 Million R&D Tax Incentive Refund to Accelerate AI Pain Assessment Platform Innovation

$1.123 Million R&D Tax Refund Bolsters PainChek’s Innovation and Market Expansion Efforts

PainChek Ltd confirmed receipt of a $1.123 million R&D tax incentive refund for the 2025 financial year, significantly enhancing the company’s liquidity. This refund was granted under the Australian Government’s R&D Tax Incentive program, which provides eligible Australian companies with a cash offset of up to 43.5% of qualifying R&D expenditures. The amount reflects substantial R&D investments PainChek made during FY2025.

The refund is directly linked to PainChek’s core mission of advancing and commercialising its AI-powered pain assessment platform. This capital injection will support ongoing product development and commercialisation initiatives, enabling the company to pursue strategic objectives without diluting shareholder equity through additional capital raises during this growth phase.

R&D Focus on Adult and Infant Algorithm Development and US Market Validation

The qualifying R&D activities that generated the tax refund included continued enhancement of PainChek’s Adult and Infant algorithms. These efforts represent significant engineering and clinical validation work aimed at broadening the platform’s applicability across diverse patient groups. Developing medical device algorithms involves extensive data science, software engineering, clinical trials, and regulatory documentation.

Additionally, the eligible R&D expenditures covered validation activities supporting PainChek’s US market entry and expansion into paediatric applications. These activities likely included clinical studies, data analysis, regulatory submissions, and FDA clearance preparation. Their qualification for the R&D tax incentive highlights the innovative nature of PainChek’s work throughout FY2025.

Global Regulatory Approvals Across Eight Jurisdictions Enable International Growth

PainChek has secured regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom, and the United States. The recent FDA De Novo clearance in the US is a landmark achievement, recognizing PainChek’s device as a novel category without a predicate in the American market.

This extensive regulatory footprint allows PainChek to pursue commercialisation across multiple developed healthcare markets, each with unique regulatory and reimbursement landscapes. Achieving clearance in these eight jurisdictions validates the device’s safety and efficacy globally and expands the company’s addressable market while mitigating single-market risks.

Strong Market Adoption: Over 2,000 Aged Care Facility Contracts and 20 Million Digital Assessments

PainChek has established contracts with more than 2,000 aged care facilities worldwide, demonstrating significant commercial validation of its technology in clinical settings. The aged care sector is a key market due to challenges in pain assessment among elderly patients with cognitive impairments and dementia.

To date, over 20 million digital pain assessments have been conducted using PainChek’s platform, reflecting widespread clinical adoption. This extensive usage provides valuable data for ongoing algorithm refinement and clinical validation, confirming the platform’s integration into healthcare workflows and its utility for caregivers and clinicians.

AI-Driven Pain Assessment Fills Critical Clinical Need for Non-Verbal Populations

PainChek’s technology is the world’s first regulatory-cleared medical device designed for pain assessment across populations unable to reliably self-report pain, including patients with dementia, developmental disabilities, unconscious individuals, and infants. This addresses a significant gap in healthcare where traditional self-report pain scales are ineffective.

By combining artificial intelligence with human clinical insight, PainChek standardises pain assessment for vulnerable groups. Its TGA and FDA approvals establish a new benchmark in pain management technology. Expanding algorithms to include paediatric applications further broadens the device’s clinical impact.

FY2025 R&D Investment Highlights Strategic Product and Market Expansion

The R&D tax incentive refund reveals PainChek’s focus on developing adult and infant algorithms, US market validation, and paediatric application expansion during FY2025. This strategy reflects management’s commitment to broadening product reach both horizontally across patient populations and vertically through technological advancement.

The timing of US validation work aligns with the company’s FDA De Novo clearance, indicating that these R&D efforts were pivotal to regulatory success. Investment in infant algorithms positions PainChek strategically within the underserved paediatric pain assessment market.

Australian R&D Tax Incentive Program Fuels Medtech Innovation

The Australian Government’s R&D Tax Incentive program, which facilitated PainChek’s $1.123 million refund, encourages domestic private sector innovation by offering cash offsets up to 43.5% of qualifying R&D spend. This support is vital for medtech firms requiring substantial upfront investment before revenue generation.

PainChek’s claimed qualifying expenditure exceeded $2.6 million in FY2025, underscoring its significant commitment to innovation. The refund provides essential working capital to accelerate development, expand teams, and fund validation without shareholder dilution.

Strategic Timing: Refund Supports Commercialisation Post-FDA Clearance

The July 2026 announcement of the R&D refund coincides with PainChek’s transition into commercialisation following FDA De Novo clearance in the US, the world’s largest medical device market. Post-approval, substantial investment in market development, education, reimbursement, and sales infrastructure is required. The refund strengthens PainChek’s financial flexibility to support these initiatives.

Receiving this refund during the commercialisation phase enables PainChek to pursue growth without immediate capital raises, preserving shareholder value. It also highlights effective management of the R&D tax incentive program and the Australian Government’s role in backing innovative medtech companies targeting global markets.

Competitive Edge as the First Regulatory-Cleared AI Pain Assessment Device

PainChek’s status as the world’s first regulatory-cleared AI-powered pain assessment device provides a significant competitive advantage. This first-mover position facilitates clinical partnerships, reimbursement development, and accumulation of clinical evidence proving efficacy.

Regulatory approvals across eight countries reinforce PainChek’s global brand and market validation. The combination of AI technology and clinical validation creates a strong barrier to entry for competitors, who must replicate extensive R&D, regulatory clearance, and clinical evidence. The platform’s 20 million assessments offer a valuable dataset for continuous improvement, further entrenching PainChek’s market position.

Upcoming Strategic Priorities: US Market Growth and Paediatric Expansion

While specific future guidance was not provided, PainChek’s R&D investments and regulatory milestones suggest key upcoming objectives include scaling US commercialisation post-FDA clearance, expanding paediatric applications leveraging infant algorithm development, and entering additional global markets.

The company’s existing contracts with over 2,000 aged care facilities offer a strong base for further penetration and upselling. Investors will likely monitor new facility contracts, usage metrics, expansion into acute and disability care settings, and reimbursement progress. The R&D tax refund strengthens PainChek’s capacity to achieve these goals, though translating regulatory success into sustained revenue growth and profitability remains a critical focus.